Splenic infarction

Verve Therapeutics Announces Interim Data for VERVE-101 Demonstrating First Human Proof-of-Concept for In Vivo Base Editing with Dose-Dependent Reductions in LDL-C and Blood PCSK9 Protein in Patients with Heterozygous Familial Hypercholesterolemia

Retrieved on: 
Sunday, November 12, 2023
Food and Drug Administration, Splenic infarction, Safety, Food, Chest pain, IND, Liver, Clinical trial, Hospital, Cardiovascular disease, Patient, Myocardial infarction, DSMB, FDA, Pharmacokinetics, Webcast, Hypercholesterolemia, Coronary catheterization, Coronary artery disease, Blood, PCSK9, Conference, Genome, Tachycardia, ASCVD, Physician, Moyamoya disease, RNA, Pharmaceutical industry, Vaccine, Copper, Medicine, Verve

BOSTON, Nov. 12, 2023 (GLOBE NEWSWIRE) -- Verve Therapeutics, Inc., a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced first human proof-of-concept data for in vivo base editing from the ongoing heart-1 phase 1b clinical trial of VERVE-101. Treatment with VERVE-101 led to dose-dependent reductions of disease-causing low-density lipoprotein cholesterol (LDL-C) in people living with heterozygous familial hypercholesterolemia (HeFH), a life-threatening inherited disease characterized by lifelong elevations in blood LDL-C and accelerated atherosclerotic cardiovascular disease (ASCVD). VERVE-101 is an investigational, in vivo base editing medicine designed to be a single-course treatment that inactivates the PCSK9 gene in the liver to durably lower blood LDL-C.

Key Points: 
  • The data showed that VERVE-101 could meaningfully and durably lower LDL-C in these patients.
  • The trial is designed to evaluate the safety and tolerability of VERVE-101, with additional analyses for pharmacokinetics and pharmacodynamic reductions in blood PCSK9 protein and LDL-C.
  • Initial safety data reported are from all ten patients enrolled as of a data cut-off date of October 16, 2023.
  • VERVE-102 is an in vivo base editing medicine that aims to inactivate the PCSK9 gene in a similar way to VERVE-101.

RION, Mayo Clinic, and the U.S. Army Medical Research Institute for Chemical Defense Receive $2.4M Department of Defense Award to Advance Exosome-Based Research in Pulmonary Therapeutics

Retrieved on: 
Monday, November 20, 2023
Other Health, Research, Technology, Defense, Hospitals, Clinical Trials, Science, Nanotechnology, Biotechnology, Veterans, Health, Military, COPD, Prevalence, Disease, ICD, Mortality, DSM-IV codes, Patient, Multimedia, Regenerative medicine, Exosome, FDA, Particulates, Wound healing, Smoke, Inhalation, Therapy, Chronic obstructive pulmonary disease, Veteran, Splenic infarction, Chemical defense, Injury, Mayo Clinic, Fire, Pharmaceutical industry

RION, a leading clinical-stage regenerative medicine company, today announced that it will collaborate with Mayo Clinic and the U.S. Army Medical Research Institute for Chemical Defense (ICD) on a $2.4M grant awarded from the Department of Defense.

Key Points: 
  • RION, a leading clinical-stage regenerative medicine company, today announced that it will collaborate with Mayo Clinic and the U.S. Army Medical Research Institute for Chemical Defense (ICD) on a $2.4M grant awarded from the Department of Defense.
  • View the full release here: https://www.businesswire.com/news/home/20231120732351/en/
    RION, located in Rochester, MN, brings extensive experience in developing and commercializing biological therapeutics.
  • The harmful gases, vapors, and/or particulate matter released by fires in war zones typically results in severe lung-induced morbidity and mortality.
  • Recent discoveries have proven that exosomes, nano-sized vesicles known for their regenerative capabilities, play a crucial role in the human body.

HeartBeam Reports Third Quarter 2023 Financial Results

Retrieved on: 
Tuesday, November 14, 2023
Data Management, Health, Medical Devices, Technology, Health Technology, Software, Cardiology, Sale, Webcast, Senior, Regulatory affairs, CFO, Boston Scientific, Common stock, Research, Algorithm, FDA, Electrophysiology, SAB, Coronary occlusion, Trial of the century, Splenic infarction, Arrhythmia, Doctor of Philosophy, Patent, United States patent law, AI, Coronavirus Scientific Advisory Board, Physician, Innovation, Medical device, Pharmaceutical industry, Cryptocurrency, Video game, MD

“During the third quarter of 2023 we significantly enhanced the HeartBeam team, continued to make steady progress toward upcoming clinical and regulatory milestones, and validated the potential of our VECG technology platform,” said Branislav Vajdic, PhD, Chief Executive Officer and Founder of HeartBeam.

Key Points: 
  • “During the third quarter of 2023 we significantly enhanced the HeartBeam team, continued to make steady progress toward upcoming clinical and regulatory milestones, and validated the potential of our VECG technology platform,” said Branislav Vajdic, PhD, Chief Executive Officer and Founder of HeartBeam.
  • Research and development expenses for the third quarter of 2023 were $1.6 million, compared to $1.6 million for the third quarter of 2022.
  • General and administrative expenses for the third quarter of 2023 were $2.1 million compared to $2.0 million for the third quarter of 2022.
  • Net loss for the third quarter of 2023 was $3.5 million, compared to a net loss of $3.6 million for the third quarter of 2022.

Cleerly, Partners Announce TRANSFORM Trial to Evaluate Personalized Heart Disease Care Strategies at American Heart Association 2023

Retrieved on: 
Saturday, November 11, 2023
Health, Technology, Health Technology, Clinical Trials, Artificial Intelligence, Pharmaceutical, Cardiology, Esperion Therapeutics, Participation, Ezetimibe, Atherosclerosis, Therapy, FAHA, Plaque, FACC, AHA, Cholesterol, Risk, CCTA, Cardiovascular disease, CAD, Tablet, Patient, Myocardial infarction, Bempedoic acid, Molina Healthcare, LDL, Type 2 diabetes, American Heart Association, University, Diagnosis, Pulmonary Vascular Research Institute, MPH, FESC, Splenic infarction, ASCVD, AI, Metabolic syndrome, Prediabetes, American Heart, Moyamoya disease, Pharmaceutical industry, Dietary supplement, Management, Medical imaging, Medicine, MD

Cleerly , the company working to create a new standard of care for the diagnosis of heart disease, today announced the TRANSFORM trial at the American Heart Association’s (AHA) 2023 Scientific Sessions.

Key Points: 
  • Cleerly , the company working to create a new standard of care for the diagnosis of heart disease, today announced the TRANSFORM trial at the American Heart Association’s (AHA) 2023 Scientific Sessions.
  • TRANSFORM is a randomized trial – sponsored by Cleerly – that aims to enroll 7,500 patients who have pre-diabetes, type 2 diabetes, or metabolic syndrome and have no symptoms of heart disease.
  • TRANSFORM aims to prove that a personalized care strategy based on a Cleerly analysis is better than usual care based on traditional cardiovascular risk factors for the primary prevention of cardiovascular events.
  • “This trial provides us the opportunity to revolutionize cardiovascular event prevention and ultimately save lives from heart disease.

Summary of opinion: Metalyse, 14/12/2023 Positive

Retrieved on: 
Monday, December 18, 2023
Bundle branch block, European Commission, Tenecteplase, Civil service commission, Intraparenchymal hemorrhage, Myocardial infarction, Medication package insert, CHMP, AMI, Marketing, AIS, Committee, Splenic infarction, Dietary supplement

On 14 December 2023, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Metalyse.

Key Points: 
  • On 14 December 2023, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Metalyse.
  • The marketing authorisation holder for this medicinal product is Boehringer Ingelheim International GmbH.
  • The CHMP adopted a new pharmaceutical form and strength (5 000 units (25 mg) powder for solution for injection) together with a new indication for the thrombolytic treatment of acute ischaemic stroke in adults.
  • Metalyse 5 000 units (25 mg) powder for solution for injection:
    Metalyse is indicated in adults for the thrombolytic treatment of acute ischaemic stroke (AIS) within 4.5 hours from last known well and after exclusion of intracranial haemorrhage.

New Poll: Arizonans Support Clean Air and Climate Action More than Ever

Retrieved on: 
Thursday, December 14, 2023
American Lung Association, Climate change, Policy, Air pollution, Investment, Risk, MediaWest*Con, Wind, Global strategy, Health, Global Strategy Group, Splenic infarction, Hearing, Stroke, Asthma, Transport, Renewable energy, PHOENIX

PHOENIX, Dec. 14, 2023 /PRNewswire/ -- Today, the American Lung Association in Arizona released updated polling that shows Arizona voters continue to support strong actions on clean air and climate change. Arizonans also overwhelmingly want to see policies to boost clean energy and solidly support efforts to encourage the transition to pollution-free vehicles.

Key Points: 
  • PHOENIX, Dec. 14, 2023 /PRNewswire/ -- Today, the American Lung Association in Arizona released updated polling that shows Arizona voters continue to support strong actions on clean air and climate change.
  • Arizonans also overwhelmingly want to see policies to boost clean energy and solidly support efforts to encourage the transition to pollution-free vehicles.
  • "Arizona has some of the worst air pollution in the U.S., which creates a myriad of respiratory and cardiovascular concerns.
  • Global Strategy group has been conducting annual polls on clean air, clean energy, and climate issues in Arizona for the last four years.

Per-Encounter Medical Market to Hit $327.84 Billion, Globally, by 2030 at 16% CAGR: Coherent Market Insights

Retrieved on: 
Thursday, December 7, 2023
DNA, Conditional sentence, Patient, Segment, Prostate, Therapy, Diagnosis, Growth, Neurology, Hospital, Stroke, DNA synthesis, ChromeOS, Telehealth, Massive parallel sequencing, Ambulatory Surgery Center Association, Food, Prevalence, Cardinal Health, Catheter, Catalent, Suture, Drug development, NGS, Synthetic biology, SPECT, Syringe, Market, Bandage, Cardiology, Research, Biotechnology, Health information management, FDG, PET, Stent, Classification, EHR, De novo, Distribution, Countertop, Cardiovascular disease, TURP, Medication, COVID-19, Death, Splenic infarction, Oncology, Beauty salon, Health insurance, Medical imaging, Pharmaceutical industry, Medical device, Geography, Endocrinology, Application, Vygon (UK)

The Per-Encounter Medical Market is influenced by various factors that drive its growth and reshape its landscape.

Key Points: 
  • The Per-Encounter Medical Market is influenced by various factors that drive its growth and reshape its landscape.
  • Request Sample Copy of this Report: https://www.coherentmarketinsights.com/insight/request-sample/6386
    Another driver boosting the growth of the Per-Encounter Medical Market is the demand for personalized healthcare services.
  • Per-encounter medical services enable healthcare providers to deliver personalized care by facilitating a one-on-one relationship between the patient and the healthcare professional.
  • Read complete market research report," Per-Encounter Medical Market, By Product Type, By Application, By Distribution Channel, By Region, and Segment Forecast 2023-2030 ", Published by Coherent Market Insights.

Per-Encounter Medical Market to Hit $327.84 Billion, Globally, by 2030 at 16% CAGR: Coherent Market Insights

Retrieved on: 
Thursday, December 7, 2023
DNA, Conditional sentence, Patient, Segment, Prostate, Therapy, Diagnosis, Growth, Neurology, Hospital, Stroke, DNA synthesis, ChromeOS, Telehealth, Massive parallel sequencing, Ambulatory Surgery Center Association, Food, Prevalence, Cardinal Health, Catheter, Catalent, Suture, Drug development, NGS, Synthetic biology, SPECT, Syringe, Market, Bandage, Cardiology, Research, Biotechnology, Health information management, FDG, PET, Stent, Classification, EHR, De novo, Distribution, Countertop, Cardiovascular disease, TURP, Medication, COVID-19, Death, Splenic infarction, Oncology, Beauty salon, Health insurance, Medical imaging, Pharmaceutical industry, Medical device, Geography, Endocrinology, Application, Vygon (UK)

The Per-Encounter Medical Market is influenced by various factors that drive its growth and reshape its landscape.

Key Points: 
  • The Per-Encounter Medical Market is influenced by various factors that drive its growth and reshape its landscape.
  • Request Sample Copy of this Report: https://www.coherentmarketinsights.com/insight/request-sample/6386
    Another driver boosting the growth of the Per-Encounter Medical Market is the demand for personalized healthcare services.
  • Per-encounter medical services enable healthcare providers to deliver personalized care by facilitating a one-on-one relationship between the patient and the healthcare professional.
  • Read complete market research report," Per-Encounter Medical Market, By Product Type, By Application, By Distribution Channel, By Region, and Segment Forecast 2023-2030 ", Published by Coherent Market Insights.

Cadrenal Therapeutics to Present at the NobleCon 19 Conference on December 4, 2023

Retrieved on: 
Thursday, November 30, 2023
Webcast, Catalog, Therapy, Patient, Death, Capital market, Conference, Florida Atlantic University, Splenic infarction, Stroke, Pharmaceutical industry, Online shopping, Noble

PONTE VEDRA, Fla., Nov. 30, 2023 /PRNewswire/ -- Cadrenal Therapeutics, Inc., (Nasdaq: CVKD), a biopharmaceutical company developing tecarfarin, a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes and deaths due to blood clots in patients with certain rare medical conditions, announced today that Quang Pham, CEO, will present at NobleCon19 - Noble Capital Markets' Nineteenth (19) Annual Emerging Growth Equity Conference at Florida Atlantic University, Executive Education Complex, in Boca Raton, FL on Monday, December 4 at 4:00 p.m. Eastern time.

Key Points: 
  • PONTE VEDRA, Fla., Nov. 30, 2023 /PRNewswire/ -- Cadrenal Therapeutics, Inc., (Nasdaq: CVKD), a biopharmaceutical company developing tecarfarin, a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes and deaths due to blood clots in patients with certain rare medical conditions, announced today that Quang Pham, CEO, will present at NobleCon19 - Noble Capital Markets' Nineteenth (19) Annual Emerging Growth Equity Conference at Florida Atlantic University, Executive Education Complex, in Boca Raton, FL on Monday, December 4 at 4:00 p.m. Eastern time.
  • There is also the opportunity to meet the management at a breakout session scheduled immediately following the presentation.
  • A high-definition video webcast of the presentation will be available the following day on the Company's website at www.cadrenal.com/investors , and as part of a complete catalog of presentations available at Noble Capital Markets' Conference website: www.nobleconference.com and on Channelchek www.channelchek.com the investor portal created by Noble.
  • The webcast will be archived on the company's website, the NobleCon website, and on Channelchek.com for 90 days following the event.

Physicians, Nurses and Other Health Professionals Urge EPA To Quickly Release Stronger Pollution Standards

Retrieved on: 
Wednesday, November 15, 2023
COPD, American Lung Association, EPA, Particulates, Heart, Infant, Climate change, PM, Nursing, Air pollution, Atmosphere of Earth, Risk, Mortality, Patient, FAAP, NAAQS, Science, Health, Lung cancer, Soot, MPH, Splenic infarction, Chronic obstructive pulmonary disease, Physician, Stroke, Illinois Environmental Protection Agency, Letter, Asthma, Life, Public, MD

WASHINGTON, Nov. 15, 2023 /PRNewswire/ -- Today, the American Lung Association delivered letters to the Environmental Protection Agency (EPA) signed by more than 1,000 physicians, nurses, public health and other health professionals to strengthen, and then quickly finalize the National Ambient Air Quality Standards (NAAQS) for particulate matter air pollution. The standards, which were supposed to be finalized last month, are overdue and urgently needed.

Key Points: 
  • In January 2023, EPA proposed new NAAQS for fine PM, which are much weaker than what scientists recommended and the public want and need to protect their health.
  • That's why we need the strongest standards possible, to fully protect health," said Anne Mellinger-Birdsong, MD, MPH, FAAP, who signed the letter.
  • "As health professionals, we do our best to help reduce the health harms impacting the communities we serve, but we cannot control the air quality.
  • Strengthening both the 24-hour and annual standards is important for achieving health and equity benefits," said one of the letters.